Eli Lilly and Company (NYSE:LLY) Position Boosted by Foundations Investment Advisors LLC

Key Points

• Foundations Investment Advisors LLC acquired an additional 6,054 shares of Eli Lilly and Company, raising its holdings by 16.3% to a total of 43,194 shares, valued at approximately $35.7 million.
• Eli Lilly reported Q1 earnings of $3.34 EPS, which missed analysts' estimates by $1.30, and experienced a 45.2% year-over-year revenue increase to $12.73 billion.
• The company announced a quarterly dividend of $1.50 per share with a yield of 0.74%, to be paid on September 10th, for shareholders of record by August 15th.

Foundations Investment Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,194 shares of the company's stock after buying an additional 6,054 shares during the quarter. Foundations Investment Advisors LLC's holdings in Eli Lilly and Company were worth $35,674,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its holdings in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter valued at $48,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.0%

NYSE:LLY traded down $15.34 on Thursday, reaching $744.74. The stock had a trading volume of 3,309,889 shares, compared to its average volume of 3,782,939. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average of $774.07 and a 200 day moving average of $800.13. The stock has a market cap of $705.82 billion, a P/E ratio of 60.75, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 earnings per share. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. Eli Lilly and Company's payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LLY shares. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.